Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China
Abrocitinib was dominant compared to dupilumab both over the short- and long-term horizon for moderate-to-severe AD in China. Future research incorporating real-world evidence and long-term efficacy outcomes could further refine these economic evaluations.
Authors
- Yanwu Zhou (ORCID: https://orcid.org/0000-0001-8552-6391)
- Liu Shao
- Haijing Guan
- Yin Shi (ORCID: https://orcid.org/0000-0002-5763-3488)
- Shuishi Li
Institutions
- Central South University (CN)
- Capital Medical University (CN)
- Peking University (CN)
- Beijing Tian Tan Hospital (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1080/13696998.2024.2403940
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.67
Funders
- Natural Science Foundation of Hunan Province